Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THOR Tuebingen choroideremia gene therapy trial
2014-005004-21Phase 2Terminated
- Sponsor
- University Hospital Tübingen
- Start
- May 2015
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of timrepigene emparvovec in choroideremia (2 arms), sponsored by University Hospital Tübingen. Primary endpoint: Anatomical and functional outcomes based on ETDRS letters. Started May 2015; status: terminated.
02
Drugs
timrepigene emparvovec
03
Conditions
choroideremia
Beyond the preview
Go deeper on 2014-005004-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005004-21.